Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease

Organic Letters

Volumn 9, Issue 16, 2007, Pages 3061-3064

  Velazquez, Francisco ^a   Venkatraman, Srikanth ^a   Wu, Wanli ^a   Blackman, Melissa ^a   Prongay, Andrew ^a   Girijavallabhan, Viyyoor ^a   Shih, Neng Yang ^a   Njoroge, F George ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; PEPTIDE; PYRROLE DERIVATIVE;

ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CYCLIZATION; ENZYMOLOGY; HEPATITIS C VIRUS; MOLECULAR MIMICRY; SYNTHESIS;

CATALYSIS; CYCLIZATION; ENZYME INHIBITORS; HEPACIVIRUS; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; PEPTIDES; PYRROLES;

EID: 34547948019     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol0711265     Document Type: Article

References (31)

1. (a) Cohen, J. Science 1999, 285, 26.
2. (b) Brown, R. S., Jr.; Gaglio, P. J. Liver Transplant. 2003, 9, S10.
3. (a) Lindenbach, B. D.; Rice, C M. Nature 2005, 436, 933.
4. (b) Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. J. Virol. 1993, 67, 3835.
5. See the following reviews and references therein: (a) Chen, S. H.; Tan, S. L. Curr. Med. Chem 2005, 12, 2317.
6. (b) Goudreau, N.; Montse, L. B. Expert Opin. Invest Drugs 2005, 14, 1129.
7. Venkatraman, S. et al. J. Med. Chem. 2006, 49, 6074.
8. BILN 2061 was the first compound to undergo clinical trials. It is also a macrocyclic inhibitor of HCV NS3 protease. See: (a) Faucher, A. M. et al. Org. Lett. 2004, 6, 2901.
9. (b) Llinas-Brunet, M. et al. J. Med. Chem. 2004, 47, 1605.
10. (a) Deiters, A.; Martin, S. F. Chem. Rev. 2004, 104, 2199.
11. (b) Tsantrizos, Y. S. J. Organomet. Chem. 2006, 691, 5163.
12. Deshmukh, P. H.; Schulz-Fademrecht, C.; Procopiou, P. A.; Vigushin, D. A.; Coombes, R. C.; Barrett, A. G. M. Adv. Synth. Catal. 2007, 349, 175.
13. Ghosh, A. K. et al. Bioorg. Med. Chem. Lett. 2005, 15, 15.
14. See the following examples and references therein for SAR of electrophilic serine traps in HCV NS3 inhibitors: (a) Bennett, J. M., et al. Bioorg. Med. Chem. Lett. 2001, 11, 355.
15. (b) Han, W.; Hu, Z.; Jiang, X.; Decicco, C. P. Bioorg. Med. Chem. Lett. 2000, 10, 711.
16. (a) Passerini, M. Gazz. Chim. Ital. 1921, 51, 126.
17. (b) Ugi, I.; Meyr, R. Chem. Ber. 1961, 94, 2229.
18. (a) Burk, M. J. J. Am. Chem. Soc. 1991, 113, 8518.
19. (b) Burk, M. J. Acc. Chem. Res. 2000, 33, 363.
20. The synthesis of 16-membered macrocycles is shown in the manuscript. See the Supporting Information for synthesis and characterization of 15- and 17-membered macrocycles.
21. For preparation of 5a using an alternative approach, see: (a) Ripka, A. S.; Bohacek, R. S.; Rich, D. H. Bioorg. Med. Chem. Lett. 1998, 8, 357.
22. (b) Goudreau, N. et al. J. Org. Chem. 2004, 69, 6185.
23. For examples of rhodium-catalyzed asymmetric hydrogenations, see: Chi, Y.; Tang, W.; Zhang, X. Modern Rhodium-Catalyzed Organic Reactions; Evans, P. A., Ed.; Wiley-VCH: Weinheim, 2005; pp 1-31.
24. Zhang, R.; Mamai, A.; Madalengoitia, J. S. J. Org. Chem. 1999, 64, 547.
25. (a) Schwab, P.; France, M. B.; Ziller, J. W.; Grubbs, R. H. Angew. Chem. Int. Ed. 1995, 34, 2039.
26. (b) Trnka, T. M.; Grubbs, R. H. Ace Chem. Res. 2001, 34, 18.
27. Allyl isocyanide can be prepared by dehydration of N-allylformamide following the procedure described for the preparation of cyclopropyl isocyanide in: Schöllkopf, U. et al. Liebigs Ann. Chem. 1976, 1, 183.
28. Dess, D. B.; Martin, J. C J. Am. Chem. Soc. 1991, 113, 7277.
29. The methyl ester analogue of 6b was used in the synthesis of oxygencontaining macrocycles.
30. A manuscript describing the synthesis and structure-activity relationship (potency and pharmacokinetic profiles) of macrocyclic inhibitors using this approach is in preparation.
31. i* and discussion, see: Morrison, J. F.; Walsh, C. T. Advances in Enzymology and Related Areas of Molecular Biology; Meister, A., Ed.; John Wiley & Sons: Hoboken, NJ, 1988; Vol. 61, pp 201.